MINNEAPOLIS--(BUSINESS WIRE)--DaVita Clinical Research® (DCR®), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, announces its one-of-a-kind Biorepository Services. These services offer the pharmaceutical industry unique collaborative research opportunities that combine access to high-quality samples combined with well-characterized patient data annotation.
DCR’s distinctive Biorepository Services support industry trends toward personalized medicine, empowered drug discovery and productive drug development for biotechnology and pharmaceutical sponsors, as well as platform technology companies. This unique approach is at the forefront of changes with the biorepository industry that will provide meaningful advances toward the future of more effective drug discovery and development.
“We are excited to begin this new chapter and believe the biorepository we are creating will set a new standard in the industry and add value to the drug discovery efforts of our partners,” stated DCR President Chris Rucker. “We believe that the unique characteristics of our offering will position us to meet a need in the discovery community that is currently not being satisfied by the existing biorepositories.”
DCR’s unique biorepository provides customized sample sets from patient populations collected nationally. These samples are collected under an IRB-approved protocol with the consent of patients. The high-quality samples contain high RNA and DNA yields and are suitable for genomic analysis. In addition, DCR collects samples under the same rigorous conditions that allow proteomic and metabolomic testing.
“Our unprecedented levels of operational excellence ensure that our partners not only have a sample for testing of the highest level of sample integrity, but the well-characterized data associated with it, including patient health history, treatment data, prescription data and hospitalization data,” said Dr. Mahesh Krishnan, M.D., DCR vice president of clinical research. “It is the characterization of our data and the annotation of this data to our sample sets that distinguish our biorepository services from the majority of the industry.”
With a staff that is fully committed to advancing the knowledge and practice of kidney care, DCR brings unsurpassed knowledge, skill and expertise to pharmaceutical research, helping facilitate the success of clinical trials.
DaVita, DaVita Clinical Research and DCR are registered trademarks of DaVita, Inc. All other trademarks are the property of their respective owners.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR) brings unsurpassed knowledge, skill, and expertise to pharmaceutical research, facilitating the success of their clients’ clinical trials. DCR’s clinical expertise ranges from designing the study to preparing and submitting the final report. DCR’s Early Clinical Research unit (Phase I-IIa) and Clinical Development network of physicians and investigative sites, Health Economics and Central Laboratory are focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas as well as CKD and ESRD populations needed to meet clinical goals. To learn more about DCR, visit www.davitaclinicalresearch.com.
About DaVita
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2011, DaVita operated or provided administrative services at 1,669 dialysis facilities, serving approximately 131,000 patients. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit www.davita.com.